Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Interventional × lanreotide × Clear all

Phase

Phase 3 11 Phase 2 8 Phase 4 5 Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Magnetic Resonance Spectroscopy 52 Cyclophosphamide 49 pembrolizumab 36 fludarabine 33 Radiotherapy 28 Biopsy 25 Nivolumab 22 Metformin 21 Bevacizumab 20 Specimen Handling 19 Fluorodeoxyglucose F18 19 Temozolomide 14 Cisplatin 14 Radiosurgery 13 Carboplatin 13 Paclitaxel 12 Letrozole 12 Fluorouracil 12 Dexamethasone 12 durvalumab 11 Radiation 11 gallium 68 PSMA-11 10 Rituximab 10 Gemcitabine 10 Etoposide 10 Doxorubicin 10 atezolizumab 9 X-Rays 9 Standard of Care 9 Positron Emission Tomography Computed Tomography 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02823691 2021-06-07

MetNET-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase EARLY_PHASE1 Unknown

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡